Infertility remains a global concern, affecting a substantial number of couples worldwide. Assisted reproductive technologies (ART) have transformed infertility treatments, yet they come with significant emotional and financial strain, outcomes are still uncertain and the treatment is often inaccessible due to high cost. These challenges underscore the urgent need for personalized, targeted solutions that go beyond ART, offering hope for women facing these complex reproductive health issues to recover potential of natural conception and healthy pregnancy. The proposal’s overarching aim is the personalization of prediction, prevention and therapeutic targets for females with unexplained infertility (uIF) and unexplained recurrent pregnancy loss (uRPL).

This project involves 5 partners from 4 countries: Innovative Medicine Centre (IMC) (Lithuania), Nanodiagnostika ltd. (NDG) (Lithuania), Medical University of Warsaw (MUW) (Poland), University College Dublin (UCD) (Ireland) and Careggi University Hospital (CUH) (Italy).

Shared etiological factors such as hormonal imbalances, uterine abnormalities, inflammatory and immunological intricacies may contribute to both uIF and uRPL, while recent collaborative efforts have identified a range of potential biomarkers related to those conditions. In this study, distinctive biomarker sets will be discerned for uIF and uRPL groups in comparison to healthy fertile women, and subtype-specific risk assessment tools and stratification strategies will be developed, which may lead to identification of personalized treatment targets for the determined pathogenetic subtypes.

Therefore, by deciphering the intricate molecular and cellular mechanisms underlying these conditions, the project strives to offer targeted and personalized solutions, advancing the field and providing hope to individuals facing the challenges of reproductive health.